U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819826) titled 'A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria' on Jan. 31.
Brief Summary: Phase III: A multicenter, randomized, double-blind, placebo-parallel controlled Phase III study evaluating the efficacy and safety of SC0062 capsule in patients with IgA nephropathy with proteinuria (SUCCESS-1).
Study Start Date: Feb. 14
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy (IgAN)
Intervention:
DRUG: SC0062 20mg dose
Subjects will take two capsules daily of one of those which are SC0062 20mg dose, SC0062 placebo for 108 weeks during the treatment period.
DRUG: Placebo of SC0062
Subjects will take two ...